ArticlePloS one2019

Comparative phenotypic profiling of the JAK2 inhibitors ruxolitinib, fedratinib, momelotinib, and pacritinib reveals distinct mechanistic signatures.

Jack W Singer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.